# First-in-Human Pilot Study of Epicardial Circular RNA-HM2002 Injection in CABG for Ischemic Heart Failure

> **NCT06621576** · EARLY_PHASE1 · COMPLETED · sponsor: **Ruijin Hospital** · enrollment: 3 (actual)

## Conditions studied

- Ischaemic Heart Disease
- Heart Failure

## Interventions

- **DRUG:** HM2002 injection

## Key facts

- **NCT ID:** NCT06621576
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-18
- **Primary completion:** 2025-05-26
- **Final completion:** 2025-05-26
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2026-05-08

## Collaborators

- Shanghai CirCode Biomed Co.,Ltd
- Shanghai Bestudy Medical Technology Co., Ltd

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06621576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06621576, "First-in-Human Pilot Study of Epicardial Circular RNA-HM2002 Injection in CABG for Ischemic Heart Failure". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT06621576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*